# OnCo record michael-postow (person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/people/michael-postow/>
  a schema:Person ;
  onco:kind "person" ;
  schema:identifier "michael-postow" ;
  schema:name "Michael A. Postow"@en ;
  schema:description "Led CheckMate 069, the first randomised trial of nivolumab plus ipilimumab, and defines how to manage immunotherapy side effects."@en ;
  schema:url <https://onco.cc/people/michael-postow/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://pubmed.ncbi.nlm.nih.gov/?term=Postow%20MA%5BAuthor%5D%20melanoma%20immune> ;
  onco:tag "melanoma", "immunotherapy", "toxicity" ;
  schema:jobTitle "Chief, Melanoma Service, Memorial Sloan Kettering Cancer Center" ;
  onco:cancers <https://onco.cc/cancers/melanoma/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/ctla4/> ;
  onco:drugs <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/> ;
  onco:institutions <https://onco.cc/institutions/mskcc/> ;
  onco:trials <https://onco.cc/trials/checkmate-067/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-asco-irae-guideline-jco-2021/> ;
  schema:affiliation <https://onco.cc/institutions/mskcc/> .